The Efficacy of the Combination Therapy with Oral and Topical Mesalazine for Patients with the First Episode of Radiation Proctitis
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Radiation proctitis is a common complication of pelvic radiation for which an optimal treatment remains undetermined. We assessed the efficacy of oral and topical mesalazine combination therapy for patients with naive radiation proctitis.
A total of 23 patients with radiation proctitis were enrolled in the study over a period of 2 years. Three of these patients were excluded due to severe bleeding during the study. Twenty patients (mean age 60.3 years; two males, 18 females) were treated with oral mesalazine (3 × 1 g per day) plus a daily mesalazine suppository (1 g per day at bedtime) for 4 weeks. The efficacy of treatment was assessed according to the Subjective Objective Management Analytic (SOMA) scale for alleviation of clinical symptoms of rectal toxicity and sigmoidoscopic findings.
The mean bleeding score improved significantly from 2.10 to 1.70 (p = 0.002) with mesalazine treatment. However, scores were not improved for pain (0.30–0.20, p = 0.163), tenesmus (0.50–0.45, p = 0.577), or stool frequency (0.35–0.30, p = 0.577). The improvements in the mean telangiectasia score (1.80–1.45, p = 0.005), bleeding point score (1.60–1.05, p < 0.001), and friable mucosa score (1.35–1.00, p = 0.005) were all statistically significant. No side-effects were noted in any of the patients.
The combination of oral and topical mesalazine therapy for radiation proctitis may be a safe and effective treatment for naive radiation proctitis, especially for hemorrhagic proctitis. A large, randomized controlled trial is required to confirm the results of this pilot study.
- Anseline PF, Lavery IC, Fazio VW, Jagelman DG, Weakly FL. Radiation injury of the rectum. Ann Surg. 1981;194:716–724. CrossRef
- Jao SW, Beart RW, Gunderson LL. Surgical treatment of radiation injuries of the colon and rectum. Am J Surg. 1986;151:272–276. CrossRef
- Ben-Josef E, Han S, Tobi M, et al. A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury. Int J Radiat Oncol Biol Phys. 2002;53:1160–1164. CrossRef
- Ben-Josef E, Han S, Tobi M, et al. Intrarectal application of amifostine for the prevention of radiation-induced rectal injury. Semin Radiat Oncol. 2002;12:81–85. CrossRef
- Henriksson R, Franzen L, Littbrand B. Effects of sucralfate on acute and late bowel discomfort following radiotherapy of pelvic cancer. J Clin Oncol. 1992;10:969–975.
- Kneebone A, Mameghan H, Bolin T, et al. The effect of oral sucralfate on the acute proctitis associated with prostate radiotherapy: a double-blind, randomized trial. Int J Radiat Oncol Biol Phys. 2001;51:628–635. CrossRef
- Kouvaris J, Kouloulias V, Malas E, et al. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy. Strahlenther Onkol. 2003;179:167–174. CrossRef
- Sanguineti G, Franzone P, Marcenaro M, et al. Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study. Strahlenther Onkol. 2003;179:464–470.
- Simone NL, Menard C, Soule BP, et al. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in quality of life measured by EPIC score. Int J Radiat Oncol Biol Phys. 2008;70:90–95. CrossRef
- Singh AK, Menard C, Guion P, et al. Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study. Int J Radiat Oncol Biol Phys. 2006;65:1008–1013. CrossRef
- Kim TO, Song GA, Lee SM, et al. Rebamipide enema therapy as a treatment for patients with chronic radiation proctitis: initial treatment or when other methods of conservative management have failed. Int J Colorectal Dis. 2008;23:629–633. CrossRef
- Baughan CA, Canney PA, Buchanan RB, Pickering RM. A randomized trial to assess the efficacy of 5-aminosalicylic acid for the prevention of radiation enteritis. Clin Oncol (R Coll Radiol). 1993;5:19–24.
- Freund U, Scholmerich J, Siems H, Kluge F, Schafer HE, Wannenmacher M. Unerwünschte Nebenwirkungen bei Anwendung von Mesalazine (5-Aminosalicylsäure) unter Strahlentherapie. Strahlenther Onkol. 1987;163:678–680.
- Kilic D, Egehan I, Ozenirler S, Dursun A. Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of sulphasalazine in preventing acute gastrointestinal complications due to radiotherapy. Radiother Oncol. 2000;57:125–129. CrossRef
- Kilic D, Ozenirler S, Egehan I, Dursun A. Sulfasalazine decreases acute gastrointestinal complications due to pelvic radiotherapy. Ann Pharmacother. 2001;35:806–810. CrossRef
- Martenson JA Jr, Hyland G, Moertel CG, et al. Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial. Int J Radiat Oncol Biol Phys. 1996;35:299–303. CrossRef
- Mennie AT, Dalley VM, Dinneen LC, Collier HO. Treatment of radiation-induced gastrointestinal distress with acetylsalicylate. Lancet. 1975;2:942–943. CrossRef
- Pobico P, Capirci C, Stevanin C, Mandoliti C, Laveder F, Rimondi AP. Acute rectal injury during pelvic RT: clinic-histological study and its prevention by 5-aminosalicylic acid. Radiother Oncol. 1994;32:S41.
- Resbeut M, Marteau P, Cowen D, et al. A randomized double blind placebo controlled multicenter study of mesalazine for the prevention of acute radiation enteritis. Radiother Oncol. 1997;44:59–63. CrossRef
- Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92:1867–1871.
- Coia LR, Myerson RJ, Tepper JE. Late effects of radiation therapy on the gastrointestinal tract. Int J Radiat Oncol Biol Phys. 1995;31:1213–1236. CrossRef
- Saclarides TJ. Radiation injuries of the gastrointestinal tract. Surg Clin North Am. 1998;77:261–268. CrossRef
- Kochhar R, Sharma SC, Gupta BB, et al. Rectal sucralfate in radiation proctitis. Lancet. 1988;13:400. CrossRef
- Kochhar R, Sriram PV, Sharma SC, et al. Natural history of late radiation proctosigmoiditis treated with topical sucralfate suspension. Dig Dis Sci. 1999;44:973–978. CrossRef
- Talley NA, Chen F, King D, Jones M, et al. Short chain fatty acids in the treatment of radiation proctitis. Dis Colon Rectum. 1997;40:1046–1050. CrossRef
- Baum CA, Biddle WL, Miner PB. Failure of 5-Aminosalicylic acid enemas to improve chronic radiation proctitis. Dig Dis Sci. 1989;34:758–760. CrossRef
- Klotz U. The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease. Eur J Clin Pharmacol. 2000;56:353–362. CrossRef
- Cole AT, Slater K, Sokal M, Hawkey CJ. In vivo rectal inflammatory mediator changes with radiotherapy to the pelvis. Gut. 1993;34:1210–1214. CrossRef
- The Efficacy of the Combination Therapy with Oral and Topical Mesalazine for Patients with the First Episode of Radiation Proctitis
Digestive Diseases and Sciences
Volume 56, Issue 9 , pp 2672-2677
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Radiation proctitis
- Industry Sectors
- Author Affiliations
- 1. Departments of Internal Medicine, Haeundae Paik Hospital, Inje University School of Medicine, 1435 Jwa-dong, Haeundae-gu, Busan, 612-030, Republic of Korea
- 2. Department of Internal Medicine, Pusan National University School of Medicine, Busan, Republic of Korea